

1 **Abstract**

2 Early diagnosis of heart failure improves patient outcomes, however diagnosis is complex
3 and often delayed. This study evaluates a digital pathway for heart failure diagnosis, showing
4 it reduces time to diagnosis and treatment initiation, with an incremental cost of £5,700 per
5 quality adjusted life-year (QALY) gained over a lifetime. The pathway is cost-effective for
6 the UK National Health Service at £20,000 per QALY threshold, however data uncertainties
7 remain.

8

9 **Keywords:** economic evaluation; heart failure; diagnostic pathways; heart failure diagnosis;
10 cost-consequence analysis; cost-effectiveness

1 **Introduction**

2 Early diagnosis and treatment of heart failure (HF) can slow disease progression,
3 avoid hospitalisations, and improve outcomes(1). However, diagnosing HF is complex and
4 often delayed; as a result, prognosis for people with HF is poor. A recent meta-analysis
5 reported survival rates at one, five and ten years to be 87%, 57% and 35%, respectively(2).
6 European and UK guidelines recommend the use of an N-terminal pro b-type natriuretic
7 peptide (NT-proBNP) blood test for patients with suspected HF in the community, to
8 determine whether and how urgently patients should be referred to standard transthoracic
9 echocardiogram (TTE) for confirmatory diagnosis(3). In practice, patients can endure
10 repeated visits to primary care and hospitals before referral, an often complex and lengthy
11 process.

12 Recent advances in digital health technologies have the potential to improve the HF
13 diagnostic pathway, including digital platforms and artificial intelligence(4). The advantages
14 of digital pathways include: redesigning and streamlining the diagnostic pathway (with added
15 benefit of data collection for audit purposes); the ability for clinicians to remotely review
16 patient results providing equity of care across geographical areas and for patients who
17 struggle to access healthcare; improving patient outcomes by reducing time to diagnosis and
18 treatment initiation; freeing TTE capacity by reducing the number of patients with suspected
19 HF referred for TTE; early diagnosis of non-HF morbidities, and optimising treatment of
20 symptoms.

21 Our study explored the potential value of introducing a digitised HF diagnostic
22 pathway compared to a usual care pathway, from the perspectives of the UK NHS and
23 patients.

24 **Methods**

25 ***Overview***

26 We developed a decision analytic model to compare the introduction of a digital
27 pathway for HF diagnosis with current practice in usual care. Patients enter the model upon
28 referral onto the HF diagnostic pathway following a NT-proBNP test. We modelled costs and
29 outcomes using a cost-consequence analysis (CCA) and a cost-utility analysis (CUA), over
30 12 months and lifetime horizons, respectively. Both the Medical Research Council (MRC)
31 guidance on developing and evaluating complex interventions(5) and the National Institute
32 for Health and Care Excellence (NICE) Evidence Standards Framework (ESF) for digital
33 health technologies(6) recognise the relevance of CCA when evaluating complex, multi-
34

1 component interventions and when other outcomes in addition to quality adjusted life years
2 (QALYs) are of interest to decision-makers.

3

4 ***Population***

5 Patients referred from primary care to the HF diagnostic pathway, with symptoms
6 suggestive of new HF and with an elevated NT-proBNP (≥ 400 pg/ml).

7

8 ***Comparator and Intervention***

9 The comparator is current practice in usual care pathway, based on the NICE HF
10 diagnosis and management guideline(7) and informed by healthcare professionals working in
11 HF diagnosis. Routine referrals should be seen within six weeks (NT-proBNP < 2000 pg/ml)
12 and urgent referrals within two weeks (NT-proBNP > 2000 pg/ml). In practice, however,
13 these referrals may take substantially longer. The HF diagnostic pathway then begins with
14 patients receiving electrocardiogram (ECG) and TTE performed by a cardiac physiologist.
15 The results of these investigations are reviewed by a cardiologist soon after. Patients
16 diagnosed with HF with reduced ejection fraction (HFrEF) and HF with preserved ejection
17 (HFpEF) are invited back to secondary care for consultation with a HF clinician to discuss
18 their diagnosis and have treatment initiated. However, patients diagnosed with HFpEF may
19 alternatively be referred back to their GP with management advice.

20

21 The digital pathway is an optimised pathway, which includes a digital platform and
22 ‘one-stop’ service for diagnosis and treatment initiation. Patients with raised NT-proBNP
23 results (> 400 pg/ml) are referred onto the digital pathway. Referral details including blood test
24 results, presentation of symptoms, and patient medical history are transferred from general
25 practice and presented on the digital platform. HF clinicians remotely review these details at
26 a stage termed Active Clinical Referral Triage (ACRT) within days of referral. Suspected HF
27 patients are invited to attend a one-stop diagnostic service, either as a ‘routine’ or ‘urgent’
28 referral. Patients not suspected to have HF exit the diagnostic pathway. Diagnosis for patients
29 with suspected HF based on ACRT is then made at the one-stop service based on ECG
30 performed by a healthcare support worker and TTE performed by a cardiac physiologist, as
31 under the usual care pathway. A cardiology nurse specialist (CNS) reviews patient
32 information and the TTE results on the digital platform, and logs a preliminary diagnosis of
33 HFrEF, HFpEF or no HF. Patients are informed of their diagnosis by the CNS, who
34 immediately initiates appropriate HF medication. Subsequently, a cardiologist remotely

1 reviews the CNS preliminary diagnosis and submits an electronic comprehensive
2 management plan to the patient's GP.


3 The intervention is informed by a digital pathway implemented during the Optimising a
4 Digital Diagnostic Pathway for Heart Failure in the Community (OPERA) study. OPERA
5 was a prospective observational study of consecutive patients who have been referred onto a
6 digital pathway for confirmation of HF diagnosis following NT-proBNP testing (1 December
7 2020 to 31 August 2021), across five outpatient sites in Glasgow, UK (Clinical trials
8 NCT04724200).

9

10 **Model**

11 A decision analytic model was developed to assess the cost-effectiveness of the digital
12 pathway (Figure 1). A decision tree accounts for outcomes under both pathways over an
13 initial period of 12 months. Patients then enter a simple long-term Markov process with risks
14 for mortality and heart failure hospitalisation conditional on their 12-month HF status (HFrEF,
15 HFpEF or no HF), over a time horizon of a further 24 annual model cycles (Figure 2). This
16 represents a total time horizon of 25 years for patients, approximating lifetime in this
17 population. The standard UK discount rate of 3.5% is applied to both costs and health
18 outcomes(8). The model is probabilistic, with relevant parameters entered as appropriate
19 probability distributions.

20



21

22 *Figure 1 Decision Analytic Model*

23

1 **Clinical data and assumptions**

2 Patients enter the model with baseline characteristics as observed in OPERA (Table 1),
3 with mean age 75 years (SE 0.359) and 51% female. Most patients had NT-proBNP
4 <2000pg/ml. The overall prevalence of HF was 81.5%, mainly with HFpEF, and NT-
5 proBNP 400-2000pg/ml.

6
7 We assumed that none of the patients with HF would be triaged out of the pathway at
8 ACRT review stage. We assumed that ACRT would accurately triage out 30% of all patients,
9 all of whom without HF(9). The total number of patients who entered ACRT was not
10 recorded in OPERA; 825 patients remained in the diagnostic pathway following ACRT (i.e.
11 assumed 70% of all patients who entered ACRT), of whom 421 were ultimately confirmed
12 not to have HF. This is equivalent to the assumption that overall, 46% of all patients without
13 HF who entered ACRT would be correctly diagnosed with no HF.

14
15 Empirical data on time to each point in the diagnostic pathways is not available. The
16 model relies on estimates provided by cardiologists and CNS involved in the OPERA study.
17 In the usual care pathway, the time from referral to TTE is estimated to be 180 days, with a
18 further 56 days for cardiologist review and subsequent cardiologist consultation. Under the
19 digital pathway ACRT is estimated to take place within six days. The interval from ACRT to
20 the one-stop diagnostic and treatment initiation service of 50 days is based on data collected
21 in OPERA. Given the uncertainties regarding the accuracy of ACRT in identifying non-HF
22 patients and in usual care timelines, both elements are a key focus in our analyses.

23
24 We based estimates of untreated HF hospitalisation rates on SOLVD for HFrEF(10)
25 and I-PRESERVE for HFpEF(11). Reduction in these risks was attributed to treatment with
26 standard of care triple therapy for HFrEF based on EMPHASIS-HF(12), with further benefit
27 from treatment with SGLT2i for HFrEF based on DAPA-HF(13), and SGLT2i based on the
28 EMPEROR preserved trial(14). HF medication confers risk reductions for HF hospitalisation
29 from initiation of treatment.

30
31 Risk of mortality is applied to all patients based on national life tables for
32 Scotland(15), with HF patients modelled to be at elevated risk based on hazard ratios in
33 comparison to the general population depending on ejection fraction, as in SOLVD and I-
34 PRESERVE(10, 11). Once treatment is initiated, however, risk reductions are applied, again

1 based on EMPHASIS-HF, DAPA-HF, and EMPEROR preserved. Some patients newly
2 diagnosed with HF may already be treated with HF relevant medication. However, we
3 assume that this will not be optimised for HF (the diagnosis not having previously been
4 made). We assume such prior medication would have negligible effect on HF mortality.

5
6 When using control group data for untreated hospitalisation and mortality from
7 SOLVD(10)and I-PRESERVE(11) we considered the following: 7% of the participants in the
8 SOLVD trial were taking beta blockers at baseline so the effects were likely small from these,
9 and whilst 85% were taking diuretics, the effect of these on lowering mortality are likely to
10 be small. Also, diuretics are not one of the current usual therapy medications for heart failure.
11 The baseline medications the participants in the I-PRESERVE trial were receiving would be
12 for co-morbidities and would not impact heart failure prognosis.

13

14 **Health related quality of life**

15 Mean health utilities measured by EQ-5D-3L in OPERA for those ultimately
16 diagnosed with HF was 0.620 (SE 0.014), representing a 17% decrement relative to the UK
17 population norm (16) of 0.755. For patients without HF we applied a UK population norm
18 accounting for reductions with increasing age and maintained the same relative reduction for
19 those with HF throughout the model. Though HF medications have been shown in clinical
20 trials to improve quality of life as measured for example by the Kansas City Cardiomyopathy
21 Questionnaire (KCCQ), we assumed no benefit of HF medication in terms of health-related
22 quality of life. We did, however, apply decrements to HF hospitalisations based on analysis
23 of the SHIFT study(17). That analysis controlled for SHIFT patients' NYHA grade and
24 estimated approximately a 0.23 (SE 0.155) reduction in quality of life for HF hospitalisation;
25 whereas the analysis applied a decrement over a period 30 days prior to and 30 days after a
26 hospitalisation, we assume a simple 30 days in total for each hospitalisation.

27

28 **Resource use**

29 Resource use for each patient referred onto the usual care pathway comprises an ECG
30 and a TTE, an associated cardiologist review (assumed to be ten minutes per review), and a
31 cardiologist out-patient consultation for final diagnosis and treatment initiation. For the
32 digital pathway, we assumed ten minutes cardiologist time per ACRT review, an ECG and a
33 TTE at the one-stop diagnosis service, with 15 minutes of a healthcare support worker's time,

1 45 minutes of a cardiac physiologist's time, 45 minutes of an CNS's time, and 15 minutes
2 cardiologist time to remotely review each patient's results. We also assumed that 25% of
3 patients attending the one-stop service will subsequently require a follow-up consultation
4 with a cardiologist.

5
6 Unit costs are presented in Table 2. Costs for the digital platform (Lenus Health)
7 include capital costs (integration of IT equipment in pathway), an annual license (which
8 covers 750 patients using the one-stop diagnostic service) and additional user fees (when the
9 number of patients exceeds 750). In the model a unit cost per patient is assigned assuming
10 1,500 patients are referred to the heart diagnosis pathway annually. Other resource use
11 through the pathways were based on standard UK unit cost sources; 2021 costs (£GBP) were
12 applied to resource estimates to calculate the average cost for each pathway. Medication
13 costs are based on British National Formulary (22). In the case of HFrEF and HFpEF the
14 standard of care four pillar treatment regimen (beta-blockers, aldosterone receptor antagonists
15 valsartan, SGLT2 inhibitors), or SGLT2 inhibitor alone is assumed respectively.

17 **Analysis**

18 We modelled short term (within 12 months) resource use and survival, and lifetime
19 cost per QALY. The main analyses were performed probabilistically. Sensitivity analyses are
20 presented based on the deterministic model.

22 **Results**

23 Results for short- and long-term are presented in Table 3.

24 **Short Term Cost-consequence Analysis**

25 Over one-year, 87.4% of patients entering the digital pathway were expected to attend
26 the one stop service and undergo echocardiography, compared to an expected 94.4% of
27 patients in the usual care pathway undergoing echocardiography, with 78.8% of patients in
28 the usual care pathway going on to consultation with a HF clinician. Total one year diagnosis
29 costs are modelled to be £67 lower for the digital pathway.

30
31 For those ultimately diagnosed with HF time to treatment and the time to diagnosis
32 was shorter with the digital pathway and led to earlier initiation of HF treatment at a mean of
33 50.4 days for the digital pathway compared with 225 days in the usual care pathway. Earlier

1 confirmation of appropriate treatment resulted in higher medication costs for the first year in
2 the digital pathway of £455 compared to £190 for usual care. Earlier treatment resulted in
3 fewer hospitalisations and lower first year mortality of 7.4% for the digital pathway
4 compared to 9.4% for usual care. Total first year costs, including hospitalisations, were £142
5 higher for the digital pathway.

6


7 **Cost-utility Analysis**

8 Reduced one year mortality in the digital pathway was extrapolated to lead to a mean
9 increase in (discounted) life expectancy of 0.105 years, or 0.056 QALYs. Greater one year
10 survival also resulted in higher lifetime treatment costs for the digital pathway of
11 approximately £350 per patient. The total incremental lifetime cost was modelled to be £323,
12 with a cost per QALY for the digital pathway of £5,732 (95% confidence interval £4,351-
13 £9,650), with a 100% probability of being cost-effective at a cost-effectiveness threshold of
14 £20,000 per QALY.

15

16 Sensitivity analysis showed the digital pathway's cost-effectiveness to be relatively
17 insensitive to replacement of base case parameter values with their 95% confidence ranges
18 (Figure 2). The digital pathway's cost-effectiveness was most sensitive to the degree of
19 benefit assigned for HF treatments, with the ICER reaching £8,748 when the upper 95%
20 confidence interval for standard of care HR for cardiovascular death in HFREF was applied.
21 When the time from referral to standard echo in the usual care pathway was assumed to be
22 131 rather 180 days the digital pathway's ICER fell marginally, to £5,333, as standard care
23 medication costs rose as a result. We applied an estimate for the rate of triage from the digital
24 pathway at ACRT of 30; alternative estimates of 20% to 40% had negligible impact on the
25 cost per QALY.

26



1

2 *Figure 2 Sensitivity Analyses*

3

1 **Discussion**

2 There is growing interest in the adoption of digital health technologies, to tackle
3 increasing pressures on healthcare systems. Healthcare commissioners are faced with early
4 adoption decisions based on limited available evidence. The introduction digital health
5 technologies to the HF diagnostic pathway is one such example.

6
7 We have conducted a comprehensive economic evaluation of the digital HF pathway
8 for diagnosis and treatment initiation compared to usual care. In the absence of empirical data
9 on comparative effectiveness, we used best available evidence from literature and from the
10 recent OPERA study. The OPERA study was a prospective observational cohort study where
11 all patients with suspected HF presenting at primary care were referred to ACRT. The study
12 has been reported to have reduced referrals for heart failure diagnostic tests, including
13 echocardiography, allowed consultants to deliver 10 clinical management plans in the time
14 required for four face to face consultations, and reduced heart failure diagnosis waiting times
15 from 12 months to six weeks(9). We applied a mid-way point of 180 days for diagnosis
16 waiting time under usual care. Nevertheless, this analysis illustrates the benefits both for
17 healthcare systems and patients that may be achieved with adoption of a digital pathway. We
18 presented the short-term costs and consequences under the alternative pathways in the
19 manner of CCA, as advocated in complex interventions and digital intervention evaluation
20 guidelines. Quantifying specific short-term outcomes such as consultant time savings and
21 diagnosis waiting times may assist health services commissioners considering the
22 implementation of innovations such as the digital pathway. Though both over the short-term,
23 and lifetime analyses, the digital pathway was associated with additional total health care
24 costs, this is due to the earlier prescription of appropriate medication, and the greater short-
25 term survival as a consequence. Short-term survival is higher in the digital pathway due to
26 earlier diagnosis, however over a life-time this incremental benefit reduces, because after one
27 year we assume equal treatment benefits in both pathways. When considering only the costs
28 for diagnosis, the digital pathway itself appears cost-saving.

29
30 There are several limitations to our study, primarily associated with the paucity of
31 data in this context. Despite existing guidelines on the usual care pathway for HF diagnosis,
32 due to healthcare systems issues, this is not implemented in practice. In addition, there is
33 heterogeneity in HF diagnostic pathways within and between different regions, making

1 identifying the usual care pathway difficult. We had to make assumptions on times from
2 referral to diagnosis and to treatment within the usual care pathway that is reflective of
3 current practice. We also made assumptions on the accuracy of TTE plus expert diagnosis
4 (either cardiologist or advance nurse practitioner) and that TTE is the gold standard for
5 diagnosis; however this is broadly in line with previous published studies (18, 19). We were
6 unable to identify recent data on comparative untreated HF treatments for mortality and
7 hospitalisations, and the data we identified for the model were old and may not be
8 representative of current observations (SOLVD and I-PRESERVE). Whilst the authors
9 acknowledge that some patients were taking medication in these trials, they concluded this
10 would not impact on heart failure prognosis, would have minimal impact on mortality and
11 was the best evidence available; participants in more recent trials, in both control and
12 treatment arms, are receiving standard care for heart failure. This justification is in line with
13 the approach used in the economic evaluation model informing current NICE heart failure
14 management recommendations(19). Finally, we used general population health utilities in our
15 model, this results in the health utilities of the HF negative group potentially being
16 overestimated as the self-reported health utilities of this cohort may not be as good as the
17 general population. We have conducted extensive sensitivity analysis to test our assumptions;
18 results remained consistent with the base case analysis.

19

20 We have adopted conservative estimates on potential benefits of the digital HF
21 pathway, where appropriate. There may be additional benefits associated with the digital
22 platform that our analysis does not consider. In our analysis we assign equivalent risks for
23 hospitalisation and mortality to all treated HF patients. However, digital pathway extends to
24 virtual clinical management which can involve ongoing collection of data and optimisation of
25 medication based on changing clinical characteristics. This may help avoid hospital
26 admissions through earlier detection of worsening heart failure, preserve health related
27 quality of life, and potentially reduce mortality.

28

29 There is potential to include artificial intelligence (AI) in the digital pathway to
30 further improve efficiency of diagnosis(20). To facilitate this requires identifying where in
31 the pathway to place AI, training on its use, and additional costs of providing this component
32 of the pathway. Introducing AI could reduce the number of people referred onto the
33 diagnostic pathway and further reduce those who go on to the one-stop service and use

1 related healthcare resources. Whilst the possible service efficiencies are clear, patient
2 outcomes would depend on the sensitivity and specificity of the AI component used.

3

4 **Conclusions**

5 This economic evaluation has estimated of the value of a digital pathway, indicating
6 adoption of an OPERA-style digital pathway is a cost-effective strategy for the NHS and the
7 patients in Scotland. However, there are varying levels of uncertainties associated with
8 limitations of available data. In order to mitigate risk of investment, decision makers might
9 consider a coverage with evidence approach, where the health technology is adopted for a
10 fixed time period with the requirement for additional data collection and an evaluation in the
11 future.

12

13 **Acknowledgements**

14 The authors of this paper would like to thank the following people for their support
15 and input to the research: Malbinder Fagura (AstraZeneca plc) and Paul McGuinness (Lenus
16 Health Ltd).

17

18 **Funding**

19 This work was funded by an unrestricted grant from AstraZeneca.

20

21 **Disclosure of interest**

22 The Health Economics and Health Technology Assessment (HEHTA) Unit at the
23 University of Glasgow (where NM, OW, AD are based) received a research grant from
24 AstraZeneca to conduct this research. MP has received research funding from Boehringer
25 Ingelheim, Roche, SQ Innovations, Astra Zeneca, Novartis, Novo Nordisk, Medtronic,
26 Boston Scientific, Pharmacosmos, and consultancy and Trial committees – Akero, Applied
27 Therapeutics, Amgen, AnaCardio, Biosensors, Boehringer Ingelheim, Novartis, Astra Zeneca,
28 Novo Nordisk, Abbvie, Bayer, Horizon Therapeutics, Takeda, Cardiorentis, Pharmacosmos,
29 Siemens, Eli Lilly, Vifor, New Amsterdam, Moderna, Teikoku, LIB Therapeutics, 3R
30 Lifesciences. DJL has received grants from AstraZeneca, Roche, Qure.ai. and has received
31 speakers honoraria from AstraZeneca and Boehringer Ingelheim. CM has received research
32 grant for OPERA (Astra Zeneca) and speaker honoraria from Astra Zeneca and Novartis. LM
33 has received funding from AstraZeneca for education talks. KB has no conflicts of interest.

1 RTC has received consultancy honoraria from Bayer for speaking honoraria from
2 AstraZeneca.

3

4 **Data availability statement**

5 Study data and model will be shared on a reasonable request to the corresponding
6 author.

7

8 **Ethics approval**

9 The OPERA study was performed according to the UK Policy Framework for Health
10 and Social Care Research and the Declaration of Helsinki and was approved by the West of
11 Scotland Research Ethics Committee (REC) (20/SW/0182) and the Health Research
12 Authority (HRA).

13

1 **References**

- 2 1. Skaner Y, Bring J, Ullman B, Strender L-E. Heart failure diagnosis in
3 primary health care: clinical characteristics of problematic patients. A clinical
4 judgement analysis study. *BMC family practice*. 2003;4:12-.
- 5 2. Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients
6 with chronic heart failure in the community: a systematic review and meta-
7 analysis. *European Journal of Heart Failure*. 2019;21(11):1306-25.
- 8 3. Cowie MR. The heart failure epidemic: a UK perspective. *Echo Research
9 and Practice*. 2017;4(1):R15-R20.
- 10 4. Li X-M, Gao X-Y, Tse G, Hong S-D, Chen K-Y, Li G-P, et al.
11 Electrocardiogram-based artificial intelligence for the diagnosis of heart failure:
12 a systematic review and meta-analysis. *Journal of Geriatric Cardiology*.
13 2022;19(12):970-80.
- 14 5. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al.
15 Framework for the development and evaluation of complex interventions: gap
16 analysis, workshop and consultation-informed update. 2021;25:57.
- 17 6. National Institute for Health and Care Excellence. Evidence Standards
18 Framework for Digital Health Technologies 2019 [Available from:
19 [https://www.nice.org.uk/Media/Default/About/what-we-do/our-
20 programmes/evidence-standards-framework/digital-evidence-standards-
21 framework.pdf](https://www.nice.org.uk/Media/Default/About/what-we-do/our-programmes/evidence-standards-framework/digital-evidence-standards-framework.pdf).
- 22 7. National Institute for Health and Care Excellence. Chronic heart failure in
23 adults: diagnosis and management - NICE guideline [NG106] 2018 [Available
24 from: <https://www.nice.org.uk/guidance/ng106>.
- 25 8. National Institute for Health and Care Excellence N. *NICE health
26 technology evaluations: the manual* 2022 [Available from:
27 <https://www.nice.org.uk/process/pmg36/chapter/economic-evaluation>.
- 28 9. NHS England. Transforming heart failure diagnosis pathway to improve
29 the patient journey: @NHStransform; 2024 [Available from:
30 [https://transform.england.nhs.uk/key-tools-and-info/digital-
31 playbooks/cardiology-digital-playbook/transforming-heart-failure-diagnosis-
32 pathway-to-improve-the-patient-journey/](https://transform.england.nhs.uk/key-tools-and-info/digital-playbooks/cardiology-digital-playbook/transforming-heart-failure-diagnosis-pathway-to-improve-the-patient-journey/).
- 33 10. Yusuf S. Effect Of Enalapril On Survival In Patients With Reduced Left-
34 Ventricular Ejection Fractions And Congestive-Heart-Failure. *New England
35 Journal of Medicine*. 1991;325(5):293-302.
- 36 11. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et
37 al. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction.
38 *New England Journal of Medicine*. 2008;359(23):2456-67.

- 1 12. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H,
2 et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
3 New England Journal of Medicine. 2011;364(1):11-21.
- 4 13. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN,
5 Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced
6 Ejection Fraction. New England Journal of Medicine. 2019;381(21):1995-2008.
- 7 14. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Boehm M, et al.
8 Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England
9 Journal of Medicine. 2021;385(16):1451-61.
- 10 15. National Records of Scotland. Life Expectancy in Scotland, 2018-2020
11 2020 [Available from: [https://www.nrscotland.gov.uk/statistics-and-](https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/life-expectancy/life-expectancy-at-scotland-level)
12 [data/statistics/statistics-by-theme/life-expectancy/life-expectancy-at-scotland-](https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/life-expectancy/life-expectancy-at-scotland-level)
13 [level](https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/life-expectancy/life-expectancy-at-scotland-level)].
- 14 16. Ara R, Brazier JE. Using Health State Utility Values from the General
15 Population to Approximate Baselines in Decision Analytic Models when
16 Condition-Specific Data are Not Available. Value in Health. 2011;14(4):539-45.
- 17 17. Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR, Sculpher M.
18 Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-
19 Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the
20 SHIFT Randomized Controlled Trial. Advances in Therapy. 2017;34(3):753-64.
- 21 18. Taylor C, Monahan M, Roalfe A, Barton P, Iles R, Hobbs Foboto R, et al.
22 The REFER (REFER for Echocardiogram) study: a prospective validation and
23 health
24 economic analysis of a clinical decision rule, NT-proBNP or their combination in
25 the diagnosis of heart failure in primary care. Efficacy Mech Eval. 2017;4(3).
- 26 19. National Institute for Health and Care Excellence. Chronic heart failure in
27 adults: diagnosis and management - NICE guideline [NG106]: addendum-
28 appendices 2018 [Available from:
29 <https://www.nice.org.uk/guidance/ng106/documents/addendum-appendices>].
- 30 20. Yasmin F, Shah SMI, Naeem A, Shujauddin SM, Jabeen A, Kazmi S, et al.
31 Artificial intelligence in the diagnosis and detection of heart failure: the past,
32 present, and future. Reviews in Cardiovascular Medicine. 2021;22(4):1095-113.
- 33 21. Jones K, Burns A. Unit Costs of Health and Social Care 2021 PSSRU,
34 University of Kent, Canterbury 2021 [Available from:
35 [https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-of-health-and-](https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-of-health-and-social-care-2021/)
36 [social-care-2021/](https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-of-health-and-social-care-2021/)].
- 37 22. UK Government. Payment by Results in the NHS: tariff for 2013 to 2014
38 2013 [Available from: [https://www.gov.uk/government/publications/payment-](https://www.gov.uk/government/publications/payment-by-results-pbr-operational-guidance-and-tariffs)
39 [by-results-pbr-operational-guidance-and-tariffs](https://www.gov.uk/government/publications/payment-by-results-pbr-operational-guidance-and-tariffs)].

- 1 23. National Health Service (England). National Schedule of NHS Costs
- 2 2020/21 2021 [Available from: [https://www.england.nhs.uk/publication/2020-](https://www.england.nhs.uk/publication/2020-21-national-cost-collection-data-publication/)
- 3 [21-national-cost-collection-data-publication/](https://www.england.nhs.uk/publication/2020-21-national-cost-collection-data-publication/).
- 4 24. British National Formulary. BNF Publications 2023 [Available from:
- 5 <https://bnf.nice.org.uk/drugs/>.
- 6

Table 1 Clinical and diagnostic model parameters

Parameter		Value	SD or 95% Confidence Interval	Source	
Patient Characteristics					
	Age	75	N/A	OPERA	
	Female	51% (n=439)	N/A		
NT-proBNP 400-2000 (N, prevalence)	Not HF	80 (18.4%)	N/A	OPERA	
	HFrEF	66 (15.2%)	N/A		
	HFpEF	219 (50.3%)	N/A		
NT-proBNP >2000 (N, prevalence)	Not HF	5 (1.1%)	N/A	OPERA	
	HFrEF	24 (5.5%)	N/A		
	HFpEF	41 (9.4%)	N/A		
Sensitivity Specificity	TTE	100% 100%	N/A	Assumption	
	ACRT	100% 46%	N/A		
Timing of Pathway Elements					
	Usual care	Referral for TTE	180 days	±27.0	Assumption
		Cardiologist review	7 days		Assumption
		Cardiologist OPC	49 days		Assumption
	Digital pathway	Referral to ACRT	6 days	±0.9	Assumption
		One-stop service	50 days	±7.5	OPERA
Heart Failure Hospitalisations					
	Annual rate of admission	HFrEF	0.219	0.202-0.237	SOLVD
		HFpEF	0.044	0.040-0.049	I_PRESERVE
	HR hospitalisation HFrEF *	Standard of Care	0.58	0.475-0.708	EMPHASIS-HF
		SGLT2i	0.70	0.590-0.830	DAPA-HF
	HR hospitalisation HFpEF	SGLT2i	0.71	0.600-0.830	EMPEROR-PRESERVED
Heart Failure Mortality					
	HR Untreated HF vs population	HFrEF	9.75	6.612-14.369	SOLVD
		HFpEF	2.15	1.461-3.174	I_PRESERVE
	Treated HFrEF (versus untreated)*	Standard care	0.44	0.278-0.696	Burnett et al (2017)
		SGLT2i	0.82	0.690-0.980	DAPA-HF
	Treated HFpEF (versus untreated)	SGLT2i	0.91	0.760-1.090	EMPEROR-PRESERVED
Distributions: age/sex: none; NT-proBNP and prevalence: Dirichlet []; ACRT specificity: beta; pathway timings: gamma; hazard ratios: lognormal.					

Table 2 Unit costs

Resource	Unit cost	Source
Digital platform	£29.05	Lenus Health (digital platform provider)
Active Clinical Referral Triage (ACRT)	£20.50	PSSRU 2021 (21)
ECG	£37.00	NHS tariffs 2013/14 (22)(uplifted to 2020/21)
Standard transthoracic echocardiogram (TTE)	£145.53	NHS reference costs 2020/21 (21)
One-stop diagnostic service	£99.80	PSSRU 2021 (21)
Cardiologist review ECG and TTE results (not using digital platform)	£20.50	PSSRU 2021 (21)
Cardiologist review of digital platform and complete management plan	£30.75	PSSRU 2021 (21)
Clinical consultation with patient for diagnosis and treatment	£257.20	NHS reference costs 2020/21 (23)
Heart failure hospitalisation	£4,093.01	NHS ref costs 2020/21 (23)
HFrEF treatment* monthly	£96.75	British National Formulary (24)
HFpEF treatment† monthly	£39.75	British National Formulary (24)

*HFrEF: Beta blockers - 50% carvedilol 50mg b.i.d; 50% bisoprolol 10mg q.d.; aldosterone receptor antagonists (MRA) - 50% spironolactone 50mg q.d.; 50% eplerenone 50mg q.d.; sacubitril/valsartan – 97mg/103mg q.d.; SGLT2i dapagliflozin or empagliflozin 10mg q.d.

†HFpEF: Sacubitril/valsartan as per HFrEF

Table 3 Outcomes and Cost-effectiveness

One-year outcomes	Digital pathway		Usual care pathway	
	Mean Units	£	Mean Units	£
ACRT	-	-	0.998	80
Echo	0.943	192	0.895	163
One-stop service	-	-	0.895	89
Clinic visit (HF clinician)	0.787	202	0.201	52
Sub-total		394		385
Hospitalisation	0.055	225	0.042	170
Time on medication		191		456
Total one-year cost		810 (651 - 969)		1,011 (917 - 1,116)
Time to diagnosis (weeks)	32 (26 - 40)		7 (6 - 9)	
One-year mortality (%)	0.095 (0.073 - 0.12)		0.076 (0.057 - 0.099)	
Long-term				
Diagnosis (year 1)		394 (380 - 407)		385 (377 - 392)
Hospitalisation		839 (529 - 1,229)		815 (498 - 1,226)
Medication		2,073 (1,342 - 2,893)		2,430 (1,683 - 3,326)
Total costs (£)		3,306 (2,316 - 4,445)		3,629 (2,629 - 4,837)
Life years		6.409 (5.033 - 8.072)		6.514 (5.093 - 8.246)
QALYs		3.588 (2.880 - 4.369)		3.645 (2.910 - 4.447)
Cost-per QALY (£)				5,732 (4,351 - 9,650)